John M. Kirkwood, MD
Professor of Medicine and Dermatology, Vice Chairman for Clinical Research, Director, Melanoma Skin and Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA
  
   
 
Learning Objectives
  • Describe major top-line findings from recent research in the use of immunotherapy and chemotherapy for metastatic melanoma
  • Identify early signs of immune-related adverse effects in patients undergoing immunotherapy for metastatic melanoma
  • List important prognostic factors in metastatic melanoma, and their role in treatment planning
  • Describe promising research that may shape the future of immunotherapy in metastatic melanoma

This program is supported by educational grant from:
The American Academy of CME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™